Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of satralizumab in neuromyelitis optica spectrum disorder
2020-003413-35Phase 3Unknown
- Sponsor
- Roche
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Roche. Primary endpoint: Incidence and severity of adverse events. Status: unknown.
02
Drugs
satralizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on 2020-003413-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003413-35.